The former CEO of Valeant Pharmaceuticals has been ordered to submit to binding arbitration his dispute with the company over allegedly unpaid stock options.
J. Michael Pearson, who left the company after eight years in May 2016, claimed in a suit that the arbitration clause in his 2015 employment agreement was superseded by terms of his separation agreement, which did not require arbitration.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
